Posts Tagged ‘Eli Lilly and Company’

That Was Quick: Zepbound Supply Running Short

April 2, 2024 — We were hopeful. Shortly after launch, it seemed like Lilly was keeping up with the demand for Zepbound – the tirzepatide brand they’re selling for obesity. But it turns out that the overwhelming need for effective obesity medicine is outstripping the supply that both Eli Lilly and Novo Nordisk can offer. Lilly told reporters on […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

LillyDirect Poised to Shake Up Access to Obesity Care

January 5, 2024 — Eli Lilly and Company has taken the unusual step of starting a direct to consumer clinical care and pharmacy program for obesity, diabetes, and migraine. If you have any doubt that LillyDirect will shake up the landscape for access to obesity care, just ask the folks at WeightWatchers. Their stock dropped by 11% yesterday when […]

The Catch-Up Game Begins in Obesity and Diabetes Medicines

November 25, 2023 — Two weeks ago, a shift started in the public messaging about semaglutide supply issues that have dogged Novo Nordisk from the very beginning of launching a version of this drug (Wegovy) for obesity. Has the catch-up game in production capacity for obesity and diabetes medicines begun at last in earnest? At the beginning of November, […]

GLP-1 Supply Issues: Both Companies on Their Toes?

November 3, 2023 — Novo Nordisk and Eli Lilly updated their investors yesterday on their performance through the third quarter of 2023 and the word is that they are “raking in cash” from their new medicines that work so well in obesity. Gobs of money seem to be flowing to both companies, but the stories they were telling about […]

OW2023: A Tantalizing Future, Inadequate in the Present

October 16, 2023 — Forgive us a bit of skepticism please. We are facing a jarring disconnect at ObesityWeek from the reality of medical care that simply can’t keep up with stunning progress in obesity science. Scientists and obesity medicine experts are promising us a tantalizing future for obesity care while the present circumstances facing real people living with […]

Obesity Care Bedlam But No Worries

August 11, 2023 — Calm in the midst of a storm is always odd. Has it passed? Or is there more to come? Bedlam pretty much defines the market for obesity care right now. Both Novo Nordisk and Lilly announced robust business results on the strength of impressive new options for treating obesity. Novo released stunning topline results for […]

From Lukewarm to Two Billion Dollars for Bimagrumab

July 15, 2023 — Four years ago, bimagrumab was a castoff from Novartis. That company had originally developed this monoclonal antibody for treating a rare muscle disease. But it failed spectacularly with disappointing results from a phase 2b study in 2016. That was a big disappointment, so it’s little wonder that Novartis walked away. Three years later, a glimmer […]

Drug Prices? Not My Fault, Say PBMs and Pharma

May 12, 2023 — Don’t look at me! That’s basically how it went at a U.S. Senate hearing Wednesday. Top executives from PBMs (pharmacy benefit managers) and the three pharma companies selling insulin testified to suggest they’re doing everything they possibly can to keep drug prices low. PBMs point the finger at pharma. Pharma executives return the favor. Lilly […]

Is Mounjaro Gliding Toward an Obesity Approval?

April 28, 2023 — Tirzepatide, marketed by Lilly under the  Mounjaro brand, may be gliding toward an FDA approval for obesity later this year. A year ago, the first phase 3 study results for tirzepatide in obesity wowed us. Yesterday, Lilly revealed yet another impressive piece of the puzzle – impressive weight reduction in persons who have both obesity […]